This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AKR963, omega-3-acid ethyl esters A
Description: ARK963 is an omega-3 based prescription drug candidate. The mechanism of action of omega-3 poly-unsaturated FAs is not completely understood, and may include: inhibition of acyl CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal b-oxidation in the liver, decreased lipogenesis in the liver (eg by acting as poor substrates for the enzymes responsible for TG synthesis), and increased plasma lipoprotein lipase activity. Gene transcription factors may also be involved in the drug's mechanism, including PPAR, SREBP-1, and ChREBP.
Pink Sheet April Full Approvals
Additional information available to subscribers only: